[The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)].
Frontotemporal dementia (FTD), characterized by neurodegeneration mainly in the frontal and temporal lobes, accounts for ca. 10-15% of all dementias. In 1892 the Czech-German neuropsychiatrist Arnold Pick reported the fi rst case of FTD in a 71-year-old patient suffering from progressive dementia, memory disturbances, and aphasia associated with frontal and temporal lobe atrophy and the presence of neuronal inclusions. Later the inclusions were named Pick bodies.The neuropathological hallmark of FTD is very differentiated. In contrast to Alzheimer's disease(AD), there are neither senile plaques nor neurofibrillary tangles in the brains of FTD patients.Frontotemporal dementias are tauopathies, a group of disorders caused by aberrant metabolism of tau protein, a family of proteins associated with microtubules (MAPT: macro-tubule-associated tau protein). In the nervous system the protein stabilizes microtubules in neuronal axons and is thus responsible for crucial processes in neuron metabolism, such as signal transduction, plasticity,and intracellular transport. In the human brain, six isoforms are produced from the MAPT gene (chromosome 17 q21.2) by alternative mRNA splicing. The isoforms differ in the number of amino acids in the protein chain, the presence of three (3R tau type) or four (4R tau type) domains responsible for binding to microtubules, and one or two inserts containing from 29 to 58 amino acids. The isoforms are modified posttranslationally by hyperphosphorylation, glycation,or oxidation, which can change the protein's properties and disturb its normal function. Altered metabolism of tau protein changes its interactions with tubulin, leading to destabilization of the microtubule structure and initiating the generation of toxic tau aggregates. The fi rst mutations in the MAPT gene responsible for frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) were found in 1998. So far over 40 mutations in the MAPT gene have been identified, mainly in families with autosomal dominant FTDP-17 but also in sporadic families with Pick's disease and AD. The known DNA changes have been classified according to their molecular effects into at least two groups: mutations that change the biochemical properties of tau protein and mutations that alter the alternative splicing of mRNA and lead very often to the overproduction of the 4R tau isoform. The imbalance in the ratio of the synthesized 3R and 4R tau isoforms stimulates protein aggregation and initiates neurodegeneration, leading to the development of dementia.
Kowalska
Anna
A
Instytut Genetyki Człowieka PAN w Poznaniu, 60-479 Poznań. annkowal@rose.man.poznan.pl
D002886:Chromosomes, Human, Pair 17; D003704:Dementia / Q000235:genetics*; D005786:Gene Expression Regulation; D006801:Humans; D020734:Parkinsonian Disorders / Q000235:genetics*; D020033:Protein Isoforms / Q000235:genetics; D016875:tau Proteins / Q000235:genetics* / Q000378:metabolism
C054369:MAPT protein, human; D020033:Protein Isoforms; D016875:tau Proteins